Switch from intravenous anti-CD20 therapy to subcutaneous ofatumumab in patients with relapsing MS: results from the OLIKOS study

Authors

Institutions

Publication Details

Journal
Journal of Neurology
Published
2025-10-24
DOI
https://doi.org/10.1007/s00415-025-13462-w
Primary Topic
Multiple Sclerosis Research Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Switch from intravenous anti-CD20 therapy to subcutaneous ofatumumab in patients with relapsing MS: results from the OLIKOS study

Benjamin Greenberg, Brandon Brown, Elizabeth Camacho, Le H. Hua et al.
Journal of Neurology
Multiple Sclerosis Research Studies
article

Switch from intravenous anti-CD20 therapy to subcutaneous ofatumumab in patients with relapsing MS: results from the OLIKOS study

Benjamin Greenberg, Brandon Brown, Elizabeth Camacho, Le H. Hua, Roland G. Henry, Enrique Álvarez, Ángel Chinea, Erik Houtsma, Natalie Moreo
article en

Abstract

No abstract available for this paper.
Journal of NeurologyVol. 272(11)
University of California, San Francisco (US), University of South Florida (US), Lou Ruvo Brain Institute (US), Novartis (United States) (US), Rocky Mountain MS Center (US), University of Colorado Anschutz Medical Campus (US), The University of Texas Southwestern Medical Center (US)
Novartis Pharmaceuticals Corporation
Openalex Percentile: Top 54%
Multiple Sclerosis Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.